Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep 3;16(17):2965.
doi: 10.3390/nu16172965.

Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress-A Pilot Study

Gerardo Bosco  1 , Alessandra Vezzoli  1   2 , Andrea Brizzolari  1 , Matteo Paganini  1 , Tommaso Antonio Giacon  1 , Fabio Savini  3 , Maristella Gussoni  2 , Michela Montorsi  2 , Cinzia Dellanoce  2 , Simona Mrakic-Sposta  2
Affiliations
Randomized Controlled Trial

Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress-A Pilot Study

Gerardo Bosco et al. Nutrients. .

Abstract

Background: Alcohol abuse is one of the most common causes of mortality worldwide. This study aimed to investigate the efficacy of a treatment in reducing circulating ethanol and oxidative stress biomarkers.

Methods: Twenty wine-drinking subjects were investigated in a randomized controlled, single-blind trial (ClinicalTrials.gov. Identifier: NCT06548503; Ethical Committee of the University of Padova (HEC-DSB/12-2023) to evaluate the effect of the intake of a product containing silymarin, pyrroloquinoline quinone sodium salt, and myricetin (referred to as Si.Pi.Mi. for this project) on blood alcohol, ethyl glucuronide (EtG: marker for alcohol consumption) and markers of oxidative stress levels (Reactive Oxygen Species-ROS, Total Antioxidant Capacity-TAC, CoQ10, thiols redox status, 8-isoprostane, NO metabolites, neopterin, and uric acid). The effects of the treatment versus placebo were evaluated acutely and after 1 week of supplementation in blood and/or saliva and urine samples.

Results: Si.Pi.Mi intake reduced circulating ethanol after 120 min (-33%). Changes in oxidative stress biomarkers, particularly a TAC (range +9-12%) increase and an 8-isoprostane (marker of lipidic peroxidation) decrease (range -22-27%), were observed too.

Conclusion: After the administration of Si.Pi.Mi, the data seemed to suggest a better alcohol metabolism and oxidative balance in response to wine intake. Further verification is requested.

Keywords: ROS; alcohol level; biomarkers; ethyl glucuronide; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest in completing this research study.

Figures

Figure 3
Figure 3
(A–C) ROS production, (D) TAC concentration assessed in plasma and (E) 8-iso-PGF2α biomarker of lipid peroxidation. Levels detected in urine, after treatment (in red) or placebo (in yellow) intake on the 1st and 7th day. Statistically significant intra (treaded: black lines; placebo: yellow line) and inter-group (purple lines) differences are displayed as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Figure 1
Figure 1
Experiment design and timeline. BIA: Bioelectrical impedance analysis.
Figure 2
Figure 2
(A) Alcohol level at 120 min after treatment (Si.Pi.Mi. in red) with respect to placebo intake (T13; 1st day; in yellow); (B) ETG level 120 min after treatment or placebo intake (T13; 1st day). Statistically significant differences are displayed as ****, p < 0.001.
Figure 4
Figure 4
Time course (mean ± SD) of (A,B) Reactive Oxygen Species (ROS) production and (C,D) Total Antioxidant Capacity (TAC) detected on saliva in ten subjects (five treated-red/white + five placebo-yellow/white). Significant intra-group differences: * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 5
Figure 5
Co Q10 plasma value after treatment (Si.Pi.Mi. in red) or placebo (yellow) intake on the 1st and 7th day.
Figure 6
Figure 6
Total and reduced GSH (A,B) and cysteine (C,D) values after treatment (Si.Pi.Mi. in red) or placebo (yellow) intake on the 1st and 7th day. Statistically significant intra (treated: black line) and inter-group (purple lines) differences are displayed as * p < 0.05; ** p < 0.01.
Figure 7
Figure 7
(A) Neopterin and (B) uric acid levels after treatment (Si.Pi.Mi. in red) intake vs. placebo (yellow). Statistically significant intra differences (treated: black line; placebo: yellow lines) are displayed as * p < 0.05.
Figure 8
Figure 8
Plots of the TAC concentration (mM) measured in plasma (in grey) versus ETG (ng·mL−1) measured in urine (in red). The linear regression fit (solid line) shows the correlation coefficient (r). A significant linear relationship (* < 0.05) was estimated.
See this image and copyright information in PMC

References

    1. Fuster D., Samet J.H. Alcohol Use in Patients with Chronic Liver Disease. N. Engl. J. Med. 2018;379:1251–1261. doi: 10.1056/NEJMra1715733. - DOI - PubMed
    1. Shen N.T., Salajegheh A., Brown R.S., Jr. A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. Hepatology. 2019;70:1038–1044. doi: 10.1002/hep.30587. - DOI - PubMed
    1. Plapp B.V. Rate-limiting steps in ethanol metabolism and approaches to changing these rates biochemically. Adv. Exp. Med. Biol. 1975;56:77–109. - PubMed
    1. Loguercio C., Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic. Biol. Med. 2003;34:1–10. doi: 10.1016/S0891-5849(02)01167-X. - DOI - PubMed
    1. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol. Aspects Med. 2008;29:9–16. doi: 10.1016/j.mam.2007.09.004. - DOI - PubMed

Publication types

Associated data

LinkOut - more resources